We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $7.15 · 3 analysts
Stored first · Google News · Yahoo Finance (English)
Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating For Longeveron? - RTTNews
Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating For Longeveron? RTTNews
Longeveron Enhances CEO Compensation and Retention Protections - TipRanks
Longeveron Enhances CEO Compensation and Retention Protections TipRanks
Longeveron Inc. (LGVN) director files Form 3 showing no share holdings - Stock Titan
Longeveron Inc. (LGVN) director files Form 3 showing no share holdings Stock Titan
Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting - Stock Titan
Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting Stock Titan
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design Stocktwits
Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership - Stock Titan
Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | — | — | — | $326K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.34 | — | — | $381K | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-2.71 | — | — | $1.79M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-3.54 | — | — | $1.02M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | Maxim Group | — | Downgrade | Buy → Hold | — | Maxim Group: Buy → Hold |
| 2026. 05. 04. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 16. | Roth Capital | — | Maintain | Buy → Buy | — | Roth Capital: Buy |
| 2025. 03. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 03. 03. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 12. 05. | Roth MKM | — | Initiate coverage | — → Buy | — | Roth MKM: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.